Pular para o conteúdo principal

First x-ray microtomography images obtained at Sirius

Two days after storing electrons in Sirius’ storage ring, the team have performed the first x-ray microtomography analysis at the new source

Two days after storing electrons in Sirius’ storage ring, the CNPEM´s team have performed the first x-ray microtomography analysis at the new Brazilian synchrotron light source. Through a simple proof of concept experiment, using less than ten thousandth of the expected power, it was possible to observe the arrival of synchrotron light for the first time in one of Sirius’ future experimental stations. This is a major milestone for the project, and a victory for Brazil’s science and technology.

“These early rock microtomography demonstrate the functionality of this great machine, designed and built by Brazilians to bring our science to a new level. Sirius is still in the early stages of commissioning, but these early tests that allowed X-ray images to be made ensure that the future will be very bright! We are very excited about the possibility to provide to the Brazilian scientific community a new level of experimental techniques as soon as possible”, said Antonio José Roque da Silva, Director General of CNPEM and the Sirius Project.

The first images were taken at one of the beamlines set up for testing, using X-ray tomography imaging techniques. These analyses mark another important milestone in the Sirius commissioning process. The team is now dedicated to achieving higher and higher currents needed to produce synchrotron light of enough intensity for the first scientific experiments.

“Even in test conditions, the high energy X-rays produced by Sirius are impressive. They will allow us to obtain higher quality images and to analyse larger samples. These conditions are so important when we plan to analyse pre-salt rocks, for example”, explains Nathaly Archilha, researcher who leads the first analyzes.

The x-rays used at the first microtomography performed at Sirius were generated by a 3.2T permanent magnet superbend source, which was developed by CNPEM’s engineering team in partnership with Brazilian companies. Sirius is the first 4th generation synchrotron light source to operate with this type of technology in the world.

At this moment, Sirius´ team has two main goals: (i) to stabilize the electron beam in the storage ring, increasing its charge to produce the even more intense synchrotron light required for the first scientific experiments; (ii) to conclude the assembly of the first beamlines, which are the research stations where scientists will conduct their experiments starting in 2020. These stations will allow researchers to study the structure of virtually any organic and inorganic materials, such as proteins, viruses, rocks, plants, soil, alloys, among many others, at the atomic and molecular scale with very high resolution and speed.





Source: Lux Eletrônico LNLS – Ano 2019 – 20 de Dezembro - CNPEM

Posted by Cláudio Henrique Dahne (Biological Sciences - UFC)

Comentários

Postagens mais visitadas deste blog

CONSERVAÇÃO DE ALIMENTOS E A EQUAÇÃO DE ARRHENIUS por Carlos Bravo Diaz, Universidade de Vigo, Espanha

Traduzido por Natanael F. França Rocha, Florianópolis, Brasil  A conservação de alimentos sempre foi uma das principais preocupações do ser humano. Conhecemos, já há bastante tempo, formas de armazenar cereais e também a utilização de azeite para evitar o contato do alimento com o oxigênio do ar e minimizar sua oxidação. Neste blog, podemos encontrar diversos ensaios sobre os métodos tradicionais de conservação de alimentos. Com o passar do tempo, os alimentos sofrem alterações que resultam em variações em diferentes parâmetros que vão definir sua "qualidade". Por exemplo, podem sofrer reações químicas (oxidação lipídica, Maillard, etc.) e bioquímicas (escurecimento enzimático, lipólise, etc.), microbianas (que podem ser úteis, por exemplo a fermentação, ou indesejáveis caso haja crescimento de agentes patogênicos) e por alterações físicas (coalescência, agregação, etc.). Vamos observar agora a tabela abaixo sobre a conservação de alimentos. Por que usamo...

Two new proteins connected to plant development discovered by scientists

The discovery in the model plant Arabidopsis of two new proteins, RICE1 and RICE2, could lead to better ways to regulate plant structure and the ability to resist crop stresses such as drought, and ultimately to improve agricultural productivity, according to researchers at Texas A&M AgriLife Research. Credit: Graphic courtesy of Dr. Xiuren Zhang, Texas A&M AgriLife Research The discovery of two new proteins could lead to better ways to regulate plant structure and the ability to resist crop stresses such as drought, thus improving agriculture productivity, according to researchers at Texas A&M AgriLife Research. The two proteins, named RICE1 and RICE2, are described in the May issue of the journal eLife, based on the work of Dr. Xiuren Zhang, AgriLife Research biochemist in College Station. Zhang explained that DNA contains all the information needed to build a body, and molecules of RNA take that how-to information to the sites in the cell where they can be used...

Fármaco brasileiro aprovado nos Estados Unidos

  Em fotomicrografia, um macho de Schistosoma mansoni, causador da esquistossomose CDC/G. Healy A agência que regula a produção de alimentos e medicamentos dos Estados Unidos, a FDA, concedeu o status de orphan drug para o fármaco imunomodulador P-Mapa, desenvolvido pela rede de pesquisa Farmabrasilis, para uso no tratamento de esquistossomose.  A concessão desse status é uma forma de o governo norte-americano incentivar o desenvolvimento de medicamentos para doenças com mercado restrito, com uma prevalência de até 200 mil pessoas nos Estados Unidos, embora em outros países possa ser maior. Globalmente, a esquistossomose é uma das principais doenças negligenciadas, que atinge cerca de 200 milhões de pessoas no mundo e cerca de 7 milhões no Brasil.  Entre outros benefícios, o status de orphan drug confere facilidades para a realização de ensaios clínicos, após os quais, se bem-sucedidos, o fármaco poderá ser registrado e distribuído nos Estados Unidos, no Brasil e em outro...